Literature DB >> 27393530

Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination.

E Andre1, C Isaacs2, D Affolabi3, R Alagna4, D Brockmann5, B C de Jong6, E Cambau7, G Churchyard8, T Cohen9, M Delmee10, J-C Delvenne11, M Farhat12, A Habib13, P Holme14, S Keshavjee15, A Khan16, P Lightfoot2, D Moore17, Y Moreno18, Y Mundade19, M Pai20, S Patel21, A U Nyaruhirira22, L E C Rocha23, J Takle24, A Trébucq25, J Creswell26, C Boehme2.   

Abstract

In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is increasing dramatically, including in resource-limited countries. Although there has never been as much digital information generated, this data source has not been exploited to its full potential. In this opinion paper, we discuss lessons learned from the global scale-up of these laboratory devices and the pathway to tapping the potential of laboratory-generated information in the field of TB by using connectivity. Responding to the demand for connectivity, innovative third-party players have proposed solutions that have been widely adopted by field users of the Xpert(®) MTB/RIF assay. The experience associated with the utilisation of these systems, which facilitate the monitoring of wide laboratory networks, stressed the need for a more global and comprehensive approach to diagnostic connectivity. In addition to facilitating the reporting of test results, the mobility of digital information allows the sharing of information generated in programme settings. When they become easily accessible, these data can be used to improve patient care, disease surveillance and drug discovery. They should therefore be considered as a public health good. We list several examples of concrete initiatives that should allow data sources to be combined to improve the understanding of the epidemic, support the operational response and, finally, accelerate TB elimination. With the many opportunities that the pooling of data associated with the TB epidemic can provide, pooling of this information at an international level has become an absolute priority.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27393530      PMCID: PMC4937753          DOI: 10.5588/ijtld.16.0015

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  15 in total

1.  E-health systems for management of MDR-TB in resource-poor environments: a decade of experience and recommendations for future work.

Authors:  Hamish S F Fraser; Ali Habib; Mark Goodrich; David Thomas; Joaquin A Blaya; Joseph Reginald Fils-Aime; Darius Jazayeri; Michael Seaton; Aamir J Khan; Sharon S Choi; Foster Kerrison; Dennis Falzon; Mercedes C Becerra
Journal:  Stud Health Technol Inform       Date:  2013

2.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.

Authors:  Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Wilbert Bara; Stanley Mungofa; Madhukar Pai; Michael Hoelscher; David Dowdy; Alex Pym; Peter Mwaba; Peter Mason; Jonny Peter; Keertan Dheda
Journal:  Lancet       Date:  2013-10-28       Impact factor: 79.321

Review 3.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

4.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

Review 5.  Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects.

Authors:  Madhukar Pai; Marco Schito
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

6.  Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.

Authors:  Angela M Starks; Enrique Avilés; Daniela M Cirillo; Claudia M Denkinger; David L Dolinger; Claudia Emerson; Jim Gallarda; Debra Hanna; Peter S Kim; Richard Liwski; Paolo Miotto; Marco Schito; Matteo Zignol
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

Review 7.  Data for action: collection and use of local data to end tuberculosis.

Authors:  Grant Theron; Helen E Jenkins; Frank Cobelens; Ibrahim Abubakar; Aamir J Khan; Ted Cohen; David W Dowdy
Journal:  Lancet       Date:  2015-10-26       Impact factor: 79.321

8.  The impact and cost of scaling up GeneXpert MTB/RIF in South Africa.

Authors:  Gesine Meyer-Rath; Kathryn Schnippel; Lawrence Long; William MacLeod; Ian Sanne; Wendy Stevens; Sagie Pillay; Yogan Pillay; Sydney Rosen
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

9.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Authors:  Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu
Journal:  BMC Infect Dis       Date:  2014-01-02       Impact factor: 3.090

10.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

Authors:  Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner
Journal:  BMJ       Date:  2009-04-30
View more
  12 in total

1.  Genotyping of Mycobacterium tuberculosis Rifampin Resistance-Associated Mutations by Use of Data from Xpert MTB/RIF Ultra Enables Large-Scale Tuberculosis Molecular Epidemiology Studies.

Authors:  Brian Weinrick
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

Review 2.  Diagnosis of opportunistic infections: HIV co-infections - tuberculosis.

Authors:  Lesley Scott; Pedro da Silva; Catharina C Boehme; Wendy Stevens; Christopher M Gilpin
Journal:  Curr Opin HIV AIDS       Date:  2017-03       Impact factor: 4.283

Review 3.  Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

Authors:  Heidi Albert; Ruvandhi R Nathavitharana; Chris Isaacs; Madhukar Pai; Claudia M Denkinger; Catharina C Boehme
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

4.  Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers.

Authors:  Nicole L Rendell; Solongo Bekhbat; Gantungalag Ganbaatar; Munkhjargal Dorjravdan; Madhukar Pai; Claudia C Dobler
Journal:  PeerJ       Date:  2017-07-14       Impact factor: 2.984

5.  Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations.

Authors:  Emmanuel André; Bouke C de Jong; Kamela C S Ng; Armand van Deun; Conor J Meehan; Gabriela Torrea; Michèle Driesen; Siemon Gabriëls; Leen Rigouts
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

6.  Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.

Authors:  Avery I McIntosh; Helen E Jenkins; Laura F White; Marinus Barnard; Dana R Thomson; Tania Dolby; John Simpson; Elizabeth M Streicher; Mary B Kleinman; Elizabeth J Ragan; Paul D van Helden; Megan B Murray; Robin M Warren; Karen R Jacobson
Journal:  PLoS Med       Date:  2018-08-21       Impact factor: 11.069

7.  Automated Real-Time Collection of Pathogen-Specific Diagnostic Data: Syndromic Infectious Disease Epidemiology.

Authors:  Mark A Poritz; Lindsay Meyers; Christine C Ginocchio; Aimie N Faucett; Frederick S Nolte; Per H Gesteland; Amy Leber; Diane Janowiak; Virginia Donovan; Jennifer Dien Bard; Silvia Spitzer; Kathleen A Stellrecht; Hossein Salimnia; Rangaraj Selvarangan; Stefan Juretschko; Judy A Daly; Jeremy C Wallentine; Kristy Lindsey; Franklin Moore; Sharon L Reed; Maria Aguero-Rosenfeld; Paul D Fey; Gregory A Storch; Steve J Melnick; Christine C Robinson; Jennifer F Meredith; Camille V Cook; Robert K Nelson; Jay D Jones; Samuel V Scarpino; Benjamin M Althouse; Kirk M Ririe; Bradley A Malin
Journal:  JMIR Public Health Surveill       Date:  2018-07-06

Review 8.  Use of Digital Technology to Enhance Tuberculosis Control: Scoping Review.

Authors:  Yejin Lee; Mario C Raviglione; Antoine Flahault
Journal:  J Med Internet Res       Date:  2020-02-13       Impact factor: 5.428

9.  Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results.

Authors:  Kamela Charmaine Ng; Conor Joseph Meehan; Gabriela Torrea; Léonie Goeminne; Maren Diels; Leen Rigouts; Bouke Catherine de Jong; Emmanuel André
Journal:  JMIR Med Inform       Date:  2018-02-27

10.  Health communication in low-income countries: A 60-year bibliometric and thematic analysis.

Authors:  Nour Mheidly; Jawad Fares
Journal:  J Educ Health Promot       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.